SCHEMBL3333676

SCHEMBL3333676

O=C(c1ccon1)N1CC2NCCCC21

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CHRNA4 P43681 2/20 0.48
CNR2 P34972 1/20 0.45
MBTD1 Q05BQ5 3/20 0.37
L3MBTL3 Q96JM7 2/20 0.37
GRM2 Q14416 5/20 0.34
CYP3A4 P08684 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.33
SCD5 Q86SK9 1/20 0.32
PARP1 P09874 1/20 0.31
IDH1 O75874 1/20 0.31
TLR9 Q9NR96 1/20 0.31
TLR8 Q9NR97 1/20 0.31
TLR7 Q9NYK1 1/20 0.31
SCD O00767 1/20 0.31
ELANE P08246 1/20 0.30
RORC P51449 1/20 0.30
KEAP1 Q14145 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3337853 0.93 CHRNA4 (0.49) CHRNA4CNR2MBTD1L3MBTL3GRM2
SCHEMBL3340625 0.88 CNR2 (0.49) CHRNA4CNR2MBTD1L3MBTL3GRM2
SCHEMBL3337598 0.82 CNR2 (0.48) CHRNA4CNR2MBTD1L3MBTL3GRM2
SCHEMBL3335443 0.82 CNR2 (0.47) CHRNA4CNR2MBTD1L3MBTL3GRM2
SCHEMBL3334246 0.80 CHRNA4 (0.62) CHRNA4CNR2MBTD1L3MBTL3GRM2
SCHEMBL3330556 0.78 CHRNA4 (0.49) CHRNA4
SCHEMBL3335026 0.76 CHRNA4 (0.48) CHRNA4MBTD1L3MBTL3GRM2
SCHEMBL3334548 0.76 CHRNA4 (0.58) CHRNA4CNR2GRM2CYP3A4
SCHEMBL3336090 0.75 CNR2 (0.49) CHRNA4CNR2GRM2SCD5SCD
SCHEMBL3333566 0.75 CHRNA4 (0.60) CHRNA4CNR2GRM2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100144700-A1 HETEROCYCLIC-CARBONYL-DIAZABICYCLOALKANES AS MODULATORS OF THE NEURONAL NICOTINIC ACETYLCHOLINE ALPHA 4 BETA 2, SUBTYPE RECEPTOR FOR THE TREATMENT OF CNS RELATED DISORDERS TARGACEPT, INC. (US) 2010-06-10 US claimed
WO-2008112734-A1 HETEROCYCLIC-CARBONYL-DIAZABICYCLOALKANES AS MODULATORS OF THE NEURONAL NICOTINIC ACETYLCHOLINE ALPHA 4 BETA 2, SUBTYPE RECEPTOR FOR THE TREATMENT OF CNS RELATED DISORDERS TARGACEPT, INC. (US) 2008-09-18 WO claimed
US-20100144700-A1 HETEROCYCLIC-CARBONYL-DIAZABICYCLOALKANES AS MODULATORS OF THE NEURONAL NICOTINIC ACETYLCHOLINE ALPHA 4 BETA 2, SUBTYPE RECEPTOR FOR THE TREATMENT OF CNS RELATED DISORDERS TARGACEPT, INC. (US) 2010-06-10 US disclosed
WO-2008112734-A1 HETEROCYCLIC-CARBONYL-DIAZABICYCLOALKANES AS MODULATORS OF THE NEURONAL NICOTINIC ACETYLCHOLINE ALPHA 4 BETA 2, SUBTYPE RECEPTOR FOR THE TREATMENT OF CNS RELATED DISORDERS TARGACEPT, INC. (US) 2008-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144700-A1 HETEROCYCLIC-CARBONYL-DIAZABICYCLOALKANES AS MODULATORS OF THE NEURONAL NICOTINIC ACETYLCHOLINE ALPHA 4 BETA 2, SUBTYPE RECEPTOR FOR THE TREATMENT OF CNS RELATED DISORDERS CHRNA10, CHRNA2, CHRNE CHRNA4 8/4885CNR2 46/4885MBTD1 3524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.